Fig. 1From: XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral diseasePatient disposition. AE, adverse event; Ev, everolimus; Ex, exemestane; PD, progressive disease; Plc, placebo; RECIST, Response Evaluation Criteria in Solid Tumors; Xe, xentuzumabBack to article page